TABLE 2.
Neuropsychiatric symptoms in residents across the COVID‐iWHELD study sample (pandemic period April 2021‐January 2022) and the WHELD study sample (pre‐pandemic period 2015‐2016), showing incidence of symptoms across the three antipsychotic frequency groups in the COVID‐iWHELD sample
| COVID‐iWHELD study sample (n = 666) | Pre‐pandemic WHELD study sample 9 (n = 1006) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Neuropsychiatric symptoms | Low antipsychotic use (N = 224) | Medium antipsychotic use (N = 225) | High antipsychotic use (N = 217) | Total sample) | |||||||
| N (%) | Mean domain score | SD | N (%) | Mean domain score | SD | N (%) | Mean domain score | SD | |||
| Delusions | 43 (19.2) | 0.79 | 2.23 | 40 (17.7) | 0.40 | 1.56 | 49 (22.6) | 1.47 | 1.56 | 132 (19.8%) | 171 (17.6%) |
| Hallucinations | 35 (15.6) | 0.98 | 2.48 | 28 (12.4) | 1.05 | 2.61 | 40 (18.4) | 1.50 | 3.20 | 103 (15.5%) | 146 (14.5%) |
| Agitation | 99 (44) | 2.10 | 3.01 | 101 (44.7) | 2.31 | 3.27 | 110 (50.7) | 2.88 | 3.59 | 310 (46.5%) | 583 (50.8%) |